BrightPath Biotherapeutics, The Current Fiscal Year Net Income Loss Widened in Downward Revision
4594 BrightPath Biotherapeutics Co., Ltd. 【J-GAAP】
Guidance Update ReportBrightPath Biotherapeutics Co., Ltd. <4594> [TSE Growth] announced a performance revision after the market closed on March 24th (18:00). The net income/loss (non-consolidated) for the fiscal year ending March 2025 has been revised downward from an expected loss of 0.92 billion yen to a loss of 1.1 billion yen (compared to a loss of 1.16 billion yen in the previous period), indicating an expansion in the loss margin.
Based on the downwardly revised full-year plan announced by the company, our calculation indicates that the October to March period (2H) net income/loss has been revised downward from an expected loss of 0.38 billion yen to a loss of 0.57 billion yen (compared to a loss of 0.61 billion yen in the same period of the previous year), indicating an expansion in the loss margin.
Kabutan News
Guidance Update
| Fiscal Year | Revenue | Operating Profit |
Ordinary Profit |
Net Profit |
Adj. EPS |
Adj. Dividend |
Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Mar, 2024 Prev | 0M | -383M | -388M | -389M | -4.4 | 0 | Nov 8, 2024 | J-GAAP |
| Oct - Mar, 2024 New | 1M | -572M | -569M | -571M | -6.4 | 0 | Mar 24, 2025 | J-GAAP |
| Revision Rate | － | -49.3% | -46.6% | -46.8% | -46.9% |
| Fiscal Year | Revenue | Operating Profit |
Ordinary Profit |
Net Profit |
Adj. EPS |
Adj. Dividend |
Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2025 Prev | 0M | -925M | -925M | -927M | -10.4 | 0 | May 10, 2024 | J-GAAP |
| Mar, 2025 New | 1M | -1,114M | -1,106M | -1,109M | -12.4 | 0 | Mar 24, 2025 | J-GAAP |
| Revision Rate | － | -20.4% | -19.6% | -19.6% | -19.7% |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit |
Ordinary Profit |
Net Profit |
Adj. EPS |
Adj. Dividend |
Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
|
|
0M | -605M | -607M | -615M | -9.6 | 0 | May 10, 2024 | J-GAAP |
|
Guidance
Oct - Mar, 2024
|
1M | -572M | -569M | -571M | -6.4 | 0 | Mar 24, 2025 | J-GAAP |
| YoY | － | +5.5% | +6.3% | +7.2% | +33.4% |
| Fiscal Year | Revenue | Operating Profit |
Ordinary Profit |
Net Profit |
Adj. EPS |
Adj. Dividend |
Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
|
|
5M | -1,467M | -1,473M | -1,485M | -24.9 | 0 | May 12, 2023 | J-GAAP |
|
|
0M | -1,155M | -1,158M | -1,168M | -18.2 | 0 | May 10, 2024 | J-GAAP |
|
Guidance
Mar, 2025
|
1M | -1,114M | -1,106M | -1,109M | -12.4 | 0 | Mar 24, 2025 | J-GAAP |
| YoY | － | +3.5% | +4.5% | +5.1% | +31.9% |
Related Articles
-
Pharmarise Holdings, Jun-Feb (Cumulative 3Q) Ordinary Profit Turns to Loss, Dec-Feb Ordinary Profit Turns to Loss
Tue Mar 25, 2025 12:00 pm JST Earnings -
The Nikkei 225 recovered to 38,000 yen level for the first time in 6 days
Tue Mar 25, 2025 9:03 am JST Market -
Nikkei 225 open on the 25th = 344 yen higher, 37,953 yen
Tue Mar 25, 2025 9:02 am JST Market -
OOMITSU, The Current Fiscal Year Ordinary Profit Revised Downward by 23%
Mon Mar 24, 2025 3:30 pm JST Earnings -
Nikkei 225 close on the 24th = falling for the 3 days in a row, 68 yen lower to 37,608 yen
Mon Mar 24, 2025 3:32 pm JST Market -
NITTO KOHKI, The Current Fiscal Year Ordinary Profit Revised Downward to an Unexpected 5% Decrease, Dividend Revised down by 9 yen
Mon Mar 24, 2025 5:00 pm JST Revision -
GSI Creos, The Current Fiscal Year Ordinary Profit Revised Downward to an Unexpected 20% Decrease, Dividend Revised Upward by 5 yen
Mon Mar 24, 2025 5:00 pm JST Revision -
Nakabohtec Corrosion Protecting, The Current Fiscal Year Ordinary Profit Revised Upward to an Unexpected 15% Increase, Highest in Four Terms, Dividend Revised Upward by 75 yen
Mon Mar 24, 2025 4:30 pm JST Revision -
Abalance, Previously Undecided Dividend for Current Fiscal Year Set at 3 yen
Mon Mar 24, 2025 4:00 pm JST Revision -
TOMOE ENGINEERING, Dividend Effectively Increased
Mon Mar 24, 2025 4:00 pm JST Revision